UK-based biopharmaceutical company, PhoreMost, is to deploy its in-house expertise and next-generation phenotypic screening platform, SITESEEKER, toward disease-relevant pathways nominated by Roche.
The virtual contract research organization (VCRO) Curavit Clinical Research has entered a long-term partnership with ixlayer. The partnership ushers in convenience for patients in Curavit’s trials.
Ensysce Biosciences has partnered with Quotient Sciences to develop an opioid to prevent abuse and overdose, enabling it to make mid-study changes to the formulation based on emerging data.
A fleet of legal professionals offers advice and perspective on important considerations when harnessing artificial intelligence and real-world evidence.
Experts from the health information specialist explain how the use of RWD and RWE has helped speed up and improve the development of therapies and vaccines.
Impel Pharmaceuticals’ Trudhesa treatment, paired with its Precision Olfactory Delivery system, reportedly shows promise to women suffering from the condition.
The Digital Medicine Society is offering a library of resources to help promote the use of nocturnal scratch as an endpoint for the troubling skin condition.
A collaboration between Touchlight and Lonza expands the Swiss CDMO’s end-to-end offering for mRNA manufacturing with an additional, differentiated source of DNA raw material, the UK biotech’s doggybone DNA (dbDNA).
The clinical-stage biotechnology company is working on the advancement of a treatment for a blood vessel disorder that it licensed from the other company
The companies will work together to help clients connect information sources, giving stakeholders a better overview of the clinical patient experience.
The pharma company’s collaboration with the drug discovery specialist involves using artificial intelligence to discover and develop up to five drug targets.
Bioprocessing 4.0 and digitalization is all about embracing new technologies to enable faster, smoother and more efficient biomanufacturing. And that also requires embracing a new mindset.
With the purchase, the company is looking to advance its plans to connect with potential trial participants and spread awareness of study participation.
The Decentralized Trials and Research Alliance is offering the research resource to increase awareness, understanding, and acceptance of the study format.
A representative from the biometric contract research organization explains how taking a ‘patient comes first’ attitude can lead to a range of improvements.
This month’s announcements of appointments, acquisitions, new hires, and other news include Standigm, Astellas Pharma, Trialbee, and other key companies.
In response to rising demand for inhalable treatments geard toward respiratory conditions, the company is adding capabilities and capacity at its Tampa site.
An expert from the company discusses how ever-changing patient needs and other dynamic factors are likely to impact pharma ingredient trends down the road.
The synthetic biology company which specializes in producing ingredients for plant-inspired medicines has a pilot-scale manufacturing facility in the works.
A company leader advises that the growing need for high-potency active pharmaceutical ingredients calls for CDMOs that consistently deliver quality at scale.
The physIQ monitoring platform will be used to evaluate an inhaled treatment, developed by InCarda, that is intended to treat atrial fibrillation patients.
A representative from the R&D tech provider offers advice on how to wrangle with a stressful, complicated process for better results and fewer headaches.
The company has landed funding from the Bill and Melinda Gates Foundation for research and development on a prototype of a refillable contraceptive solution.
The company reports dosing of the first subject in a Phase IIa proof-of-concept study investigating a drug for an autism spectrum disorder related condition.
The National Institutes of Health grant to AVM Biotechnology will be used to evaluate a drug to treat non-Hodgkin’s lymphoma combined with standard of care.
The pharmaceutical company and the artificial intelligence pathology specialist will focus on translational research in oncology, fibrosis, and immunology.
A leader suggests considering patient views and needs all along the clinical development path reaps a number of benefits, including time and cost savings.
The group’s latest report glimpses inside the minds of pharma leaders, who are looking at a product’s full life-cycle development at the preclinical stage.
This month’s news on technology, partnerships, expansions, and more includes items from IQVIA, Almac Group, Signant Health, Lonza, and other key companies.
The group has introduced a downloadable guide, interactive quiz, and other tools to inform patients from underrepresented communities about trial participation.
A leader from the trial financial management specialist suggests apps used in trials could be adjusted to better suit patients, sites and other stakeholders.
The pharmaceutical company has completed acquisition of Turning Point Therapeutics, a company specializing in precision medicine solutions for cancer patients.
The National Institute for Health and Care Excellence is weighing the viability of PD Neurotechnology’s PDMonitor system for Parkinson’s disease patients.
The AI and QC specialists have joined to use AI and QC in order to discover biological pathways relevant to the treatment of triple-negative breast cancer.
An expert from the clinical insight specialist shares how predictive analytics could reveal info about medication adherence, disease progression, and more.
Signant Health has partnered with the software company o connect its platforms for the management of clinical supply chain inventory, labels, and content.
The purchase brings under the UPS Healthcare umbrella several temperature-controlled facilities in 14 countries situated throughout Europe and Latin America.
The pharmaceutical company has inked a strategic collaboration with the drug discovery firm, centering on uncovering novel targets in Alzheimer’s disease.
A leader from the behavioral science specialist shares ways to use precision engagement and other methods to increase patient adherence in clinical studies.
After scientists and reporters raised red flags about a study, Cassava Sciences is being accused of falsifying data in pursuit of an Alzheimer’s treatment.
The two companies are collaborating to generate subject data sets designed to help users find insights that can speed up research and improve patient care.
Biopharmaceutical company Global Blood Therapeutics specializes in conditions that often disproportionately impact underrepresented communities, such as SCD.
The pharmaceutical company has forged a partnership with the nanotechnology specialist to use nanoparticle tech and formulation to advance its products.
This month’s announcements of appointments, partnerships, expansions, and mergers include Curia, Thread, TFF Pharmaceuticals, and other notable companies.
An expert from the trial tech firm explains how the 21st Century Cures Act and other recent regulatory advancements can elevate clinical data registries.
The pharmaceutical company has forged a partnership with the life-sciences tech firm in an effort to elevate data collection and speed up clinical studies.